Tracking leukemia stem cells in blood for acute myeloid leukemia treatment
Prospective Study of Leukemia Stem Cells Fractional Change in Peripheral Blood and Its Correlation With Therapeutic Outcome in Acute Myeloid Leukemia
This study is testing if checking for certain leukemia markers in the blood can help doctors predict how well treatment will work for people with acute myeloid leukemia.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Stony Brook University Academic / other |
| Locations | 1 site (Stony Brook, New York) |
| Trial ID | NCT06297551 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the potential of using leukemia stem cell markers, specifically CLL1 and CD45RA, found in peripheral blood as a non-invasive method to predict treatment outcomes in patients with acute myeloid leukemia (AML). Traditionally, treatment decisions are based on invasive bone marrow biopsies performed at the end of each treatment cycle. By monitoring these markers early in the treatment cycle, the study seeks to provide timely insights that could guide therapeutic regimen selection and improve patient care. The study will quantify the presence of these markers using flow cytometry to assess their correlation with treatment efficacy.
Who should consider this trial
Good fit: Ideal candidates for this study are adults diagnosed with acute myeloid leukemia who are eligible for treatment at the research center.
Not a fit: Patients who do not have elevated levels of CLL1A and CD45RA positive cells at the time of diagnosis may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective treatment strategies for patients with acute myeloid leukemia.
How similar studies have performed: While the use of biomarkers in leukemia treatment is an evolving field, this specific approach of tracking leukemia stem cells in peripheral blood is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * diagnosis of acute myeloid leukemia * ability to receive treatment for acute myeloid leukemia at the research center * elevated values of CLL1A and CD45RA positive cells at the time of diagnosis
Where this trial is running
Stony Brook, New York
- Stony Brook Cancer Center — Stony Brook, New York, United States (Recruiting)
Study contacts
- Principal investigator: Suhu Liu, MD PhD — Stony Brook Medicine
- Study coordinator: Caterina Vacchi-Suzzi, PhD
- Email: cancerclinicaltrials@stonybrookmedicine.edu
- Phone: 631-728-7425
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.